Trial Profile
A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors MedImmune
- 04 Jun 2019 Results assessing pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.